Personalized Medical Care & Dedicated International Patient Concierge
Medical Guide
Wegovy vs Mounjaro vs Saxenda: GLP-1 Drugs Compared
Compare Wegovy, Mounjaro, and Saxenda: how these GLP-1 medicines differ in FDA-approved use, dosing, and side effects, and why doctor supervision matters.
Schedule a ConsultationWegovy vs Mounjaro vs Saxenda: GLP-1 Drugs Compared
Medically reviewed by Dr. Jeong Seo In, Board-Certified Internal Medicine Specialist, Cheongdam Idun Clinic
Wegovy, Mounjaro, and Saxenda are three of the most talked-about injectable medicines in metabolic health today. They are often mentioned in the same breath, which can make them seem interchangeable. They are not. They contain different active ingredients, work through overlapping but not identical pathways, are dosed differently, and, importantly, carry different United States regulatory approvals. Understanding these differences helps you have a more informed conversation with a physician about what, if anything, is appropriate for you.
This article compares the three medicines in plain language: how they work, how they are taken, what side effects are common, and what their FDA-approved uses actually are. It is educational only. These are prescription medicines that require an individual medical evaluation and ongoing supervision, and none of them is a cosmetic treatment or a guaranteed result.
The class: what GLP-1 medicines do
All three medicines belong to a family of drugs that act on gut-hormone pathways involved in appetite and blood sugar. GLP-1 (glucagon-like peptide-1) is a hormone released after eating that promotes a sense of fullness, slows how quickly the stomach empties, and helps regulate blood sugar. Medicines that mimic GLP-1 can help many people feel less hungry and eat less. One of the three medicines discussed here acts on a second gut-hormone pathway as well, which is part of why the class continues to evolve.
Because different brand names can contain the same or related ingredients, and because the same ingredient can be approved for different conditions, precision matters. Here is the key distinction stated plainly: in the United States, Wegovy (semaglutide) and Saxenda (liraglutide) are FDA-approved for chronic weight management, while Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes; the tirzepatide product approved for weight management in the United States is Zepbound. Keeping that straight is essential when reading about these medicines online.
Wegovy (semaglutide)
Wegovy contains semaglutide, a GLP-1 receptor agonist. In the United States it is FDA-approved for chronic weight management in eligible adults and in adolescents aged 12 and older, used together with a reduced-calorie diet and increased physical activity. It is given as a once-weekly injection under the skin, with the dose increased gradually over time to help the body adjust and to reduce side effects.
Semaglutide is also sold under other brand names and dosages for different purposes. As injectable Ozempic and oral Rybelsus, semaglutide is FDA-approved to treat type 2 diabetes. This is a good example of why brand names matter: the same active ingredient can appear in different products approved for different conditions. Only a prescribing clinician should decide which product, if any, is suitable for a given person.
Mounjaro (tirzepatide) and its relationship to Zepbound
Mounjaro contains tirzepatide, which is described as a dual agonist because it acts on two gut-hormone receptors, GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). In the United States, Mounjaro is FDA-approved for type 2 diabetes, where it is used alongside diet and exercise to improve blood-sugar control. It is given as a once-weekly injection with gradual dose increases.
The same active ingredient, tirzepatide, is marketed in the United States as Zepbound for chronic weight management. In other words, Mounjaro and Zepbound share the ingredient tirzepatide but carry different FDA-approved indications: Mounjaro for type 2 diabetes and Zepbound for chronic weight management. This distinction is frequently blurred in casual conversation and online, so it is worth repeating clearly. If you have seen tirzepatide described as a weight-loss drug, the product FDA-approved for that use in the United States is Zepbound, not Mounjaro.
Saxenda (liraglutide)
Saxenda contains liraglutide, a GLP-1 receptor agonist. In the United States it is FDA-approved for chronic weight management in eligible adults and in adolescents aged 12 and older, used with a reduced-calorie diet and increased physical activity. Unlike the once-weekly options above, Saxenda is a daily injection, so it requires a consistent everyday routine.
Liraglutide is also available at a lower dose under the brand name Victoza, which is FDA-approved to treat type 2 diabetes. As with semaglutide, the same molecule appears in more than one product with different approved uses and dosing. The right choice depends on an individual's health profile, medical history, and goals, which is a decision to be made with a clinician rather than from an article.
How they compare at a glance
Rather than ranking these medicines, it is more useful to understand how they differ so you can ask better questions. A few practical points of comparison:
- Active ingredient: Wegovy is semaglutide; Mounjaro and Zepbound are tirzepatide; Saxenda is liraglutide.
- Mechanism: Wegovy and Saxenda act on the GLP-1 pathway; tirzepatide acts on both GLP-1 and GIP pathways.
- Dosing rhythm: Wegovy and Mounjaro are once weekly; Saxenda is once daily. All are injections given under the skin and are titrated upward gradually.
- FDA-approved use in the United States: Wegovy and Saxenda for chronic weight management; Mounjaro for type 2 diabetes; Zepbound (tirzepatide) for chronic weight management.
Clinical trials have reported meaningful average weight changes with these medicines when used with lifestyle measures, and published figures for prescription weight-management drugs generally describe average losses in the range of several percent up to roughly 15 percent or more of starting body weight over about a year, depending on the medicine and the person. These figures come from clinical trials and product labeling and describe averages across study populations. They are not a promise of any particular result, and individual outcomes vary widely. No clinic can guarantee a specific amount of weight loss.
Who might be considered for treatment
Prescription weight-management medicines are not intended for everyone who wants to lose a few pounds, and they are certainly not cosmetic. In general, clinicians consider these medicines for adults whose weight is affecting their health, using body mass index (BMI) as one part of the assessment. Published guidance commonly describes eligibility for chronic weight-management medicines in adults with a BMI of 30 or greater, or a BMI of 27 or greater when accompanied by a weight-related health problem such as high blood pressure, high cholesterol, or type 2 diabetes. Some of these medicines are also studied and approved for adolescents, but that is a separate and carefully considered decision.
Being eligible on paper is only the starting point. A clinician also reviews your full medical history, current medications, personal and family history of conditions such as thyroid cancer, and whether you are pregnant or planning a pregnancy. These medicines work best as part of a plan that includes healthy eating and physical activity, and studies consistently show they are more effective when paired with those lifestyle measures than when used alone. For people who are not candidates for medication, or who prefer to start elsewhere, a structured lifestyle program may be a reasonable first step. This individualized judgment is exactly why a face-to-face medical evaluation, rather than an online questionnaire, is the appropriate way to decide whether any of these medicines is suitable.
Side effects and safety
The most common side effects across this class are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. These tend to be most noticeable early in treatment or when the dose is increased, and they often ease over time. Starting at a low dose and increasing slowly is one reason clinicians titrate these medicines carefully.
There are also important safety considerations that apply broadly across this class. These medicines carry a warning regarding a personal or family history of medullary thyroid carcinoma (a type of thyroid cancer) or the genetic condition multiple endocrine neoplasia syndrome type 2 (MEN 2). Rare but serious problems such as pancreatitis, gallbladder disease, or allergic reactions can occur. They are not recommended during pregnancy or when planning a pregnancy. Because these medicines can slow stomach emptying, they may affect how other oral medicines are absorbed. All of this underscores why a full medical history and physician oversight are necessary before and during treatment. If you want to understand how supervised metabolic care is organized, you can reach out through the clinic contact page.
Why physician supervision matters
None of these medicines is a stand-alone solution, and none is cosmetic. They are prescription treatments intended to be part of a broader plan that includes healthy eating, physical activity, and regular follow-up. A clinician assesses whether treatment is appropriate, selects among options based on your health profile, monitors for side effects, and adjusts the plan over time. Because the effects depend on ongoing use, and because weight regain is common after stopping, long-term planning is part of responsible care.
At Cheongdam Idun Clinic, weight-management options including Wegovy, Mounjaro, and Saxenda are offered within physician-led, individualized care rather than as products to be picked from a menu. The purpose of comparing these medicines is not to declare a winner but to help you understand the landscape well enough to have a productive discussion with a qualified physician. You can learn more about the clinic's approach on the Cheongdam Idun Clinic website.
Frequently Asked Questions
Are Wegovy and Ozempic the same drug?
Both contain the active ingredient semaglutide, but they are different products with different FDA-approved uses. Wegovy is FDA-approved for chronic weight management, while Ozempic is FDA-approved for type 2 diabetes. A prescribing clinician determines which product, if any, is appropriate.
Is Mounjaro approved for weight loss in the United States?
In the United States, Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes. The tirzepatide product FDA-approved for chronic weight management in the United States is Zepbound. They share the same active ingredient but carry different approved indications.
Which of these medicines is the best?
There is no single best option, because the right choice depends on your individual health profile, medical history, and goals. Each medicine has different ingredients, dosing, and approved uses, and each has benefits and risks. This is a decision to make with a physician after a thorough evaluation.
How are these medicines taken?
All three are injections given under the skin. Wegovy and Mounjaro are taken once weekly, while Saxenda is taken once daily. In each case the dose is increased gradually over time to help reduce side effects, and treatment should be supervised by a clinician.
What are the most common side effects?
Gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, and abdominal discomfort are the most common across this class. They are often most noticeable early or after a dose increase and tend to improve over time. Serious effects are less common but possible, which is why supervision matters.
Will the weight stay off after I stop?
The effects of these medicines depend on ongoing use, and many people regain some weight after stopping. Maintaining healthy eating and physical activity habits can help limit weight regain. Any decision to start or stop treatment should be made with your physician.
The Bottom Line
- Wegovy (semaglutide) and Saxenda (liraglutide) are FDA-approved for chronic weight management; Mounjaro (tirzepatide) is FDA-approved for type 2 diabetes, and Zepbound is the tirzepatide product approved for weight management in the United States.
- The medicines differ in active ingredient, mechanism, and dosing rhythm: Wegovy and Mounjaro are once weekly, and Saxenda is once daily.
- Common side effects are gastrointestinal, and there are important contraindications, including a personal or family history of medullary thyroid carcinoma or MEN 2.
- Clinical-trial figures describe averages, not promises; individual outcomes vary and no specific result can be guaranteed.
- These are prescription medicines that require an individual evaluation and ongoing physician supervision, not cosmetic products.
This article is for educational purposes only and is not medical advice. It is not a self-diagnosis tool. Regulatory status reflects United States FDA information at the time of writing, some uses may differ by product, and individual outcomes vary. Always consult a qualified physician before starting, changing, or stopping any treatment.
More Articles
Continue reading our clinical guides.
Functional Medicine Panel in Seoul Cheongdam Idun Clinic
Discover what is included in a comprehensive functional medicine panel at Cheongdam Idun Clinic in Seoul. Expert biomarker testing led by Asan trained doctors.
Learn More
Botox Seoul 2026: Costs Results And Expert Clinic Guide
Discover the definitive 2026 guide to botox Seoul at Cheongdam Idun Clinic. Get expert insights on costs results and safety from Asan Medical Center specialists.
Learn More
NAD+ IV Therapy for Cellular Energy: An Honest Primer
Learn how NAD+ IV therapy is marketed for cellular energy and aging, what the limited evidence shows, why it is not FDA-approved, and the risks to weigh.
Learn More